Phase Ib trial of CALAA 01 to investigate an alternative dosing regimen in patients with solid tumours that are refractory to standard-of-care therapies.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2012

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CALAA 01 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Calando Pharmaceuticals

Most Recent Events

30 Aug 2012 Status changed from planning to active, no longer recruiting, according to an Arrowhead Research Corporation media release.
15 Aug 2012 Additional patients were dosed, according to an Arrowhead Research Corporation media release.
16 Aug 2011 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight